Bharat Biotech seeks DCGI’s nod for its intranasal COVID-19 booster dose clinical trials
As India is witnessing a surge in cases of Omicron variant, Hyderabad-based Bharat Biotech has submitted the phase 3 clinical trial application to the Drugs Controller General of India (DCGI) to get approval for the booster dose of their…
Read More...
Read More...